BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38063980)

  • 1. Screening history and risk of death from prostate cancer: a nested case-control study within the screening arm of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC).
    Talala K; Walter S; Taari K; Tammela TLJ; Kujala P; Auvinen A
    Cancer Causes Control; 2024 Apr; 35(4):695-703. PubMed ID: 38063980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
    Pakarainen T; Raitanen J; Talala K; Taari K; Kujala P; Tammela TL; Auvinen A
    Eur Urol; 2016 Sep; 70(3):499-505. PubMed ID: 27210461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC).
    Pakarainen T; Nevalainen J; Talala K; Taari K; Raitanen J; Kujala P; Stenman UH; Tammela TLJ; Auvinen A
    Cancer; 2021 Jan; 127(2):188-192. PubMed ID: 33048394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer.
    Ola IO; Talala K; Tammela T; Taari K; Murtola T; Kujala P; Raitanen J; Auvinen A
    Int J Cancer; 2023 Feb; 152(4):672-678. PubMed ID: 36056577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC).
    Pakarainen T; Nevalainen J; Talala K; Taari K; Raitanen J; Kujala P; Stenman UH; Tammela TLJ; Auvinen A
    Clin Cancer Res; 2019 Jan; 25(2):839-843. PubMed ID: 30322875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
    Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):483-490. PubMed ID: 30696944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
    PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of prostate cancer screening among men using antidiabetic medication.
    Vettenranta A; Murtola TJ; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
    Sci Rep; 2021 Apr; 11(1):7363. PubMed ID: 33795720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.
    Wu GH; Auvinen A; Yen AM; Hakama M; Tammela TL; Stenman UH; Kujala P; Ruutu M; Chen HH
    Eur Urol; 2012 May; 61(5):1011-8. PubMed ID: 22264679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
    Murtola TJ; Kasurinen TVJ; Talala K; Taari K; Tammela TLJ; Auvinen A
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):66-76. PubMed ID: 30214034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Prostate-specific Antigen-based Prostate Cancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs.
    Murtola TJ; Vettenranta AM; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
    Eur Urol Focus; 2018 Dec; 4(6):851-857. PubMed ID: 28753870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
    Haring A; Murtola TJ; Talala K; Taari K; Tammela TL; Auvinen A
    Scand J Urol; 2017 Feb; 51(1):5-12. PubMed ID: 28084175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
    Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Villers A; Bessaoud F; Trétarre B; Grosclaude P; Malavaud B; Rebillard X; Iborra F; Daubisse L; Malavaud S; Roobol M; Heijnsdijk EA; de Koning HJ; Hugosson J; Rischmann P; Soulié M
    Prog Urol; 2020 Apr; 30(5):252-260. PubMed ID: 32197936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
    Hugosson J; Roobol MJ; Månsson M; Tammela TLJ; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Carlsson SV; Talala KM; Lilja H; Denis LJ; Recker F; Paez A; Puliti D; Villers A; Rebillard X; Kilpeläinen TP; Stenman UH; Godtman RA; Stinesen Kollberg K; Moss SM; Kujala P; Taari K; Huber A; van der Kwast T; Heijnsdijk EA; Bangma C; De Koning HJ; Schröder FH; Auvinen A;
    Eur Urol; 2019 Jul; 76(1):43-51. PubMed ID: 30824296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer.
    Salminen JK; Mehtola A; Talala K; Taari K; Mäkinen J; Peltola J; Tammela TLJ; Auvinen A; Murtola TJ
    Br J Cancer; 2022 Sep; 127(4):704-711. PubMed ID: 35505251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
    de Vos II; Meertens A; Hogenhout R; Remmers S; Roobol MJ;
    Eur Urol; 2023 Oct; 84(4):426-434. PubMed ID: 37029074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.
    Murtola TJ; Sälli SM; Talala K; Taari K; Tammela TLJ; Auvinen A
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):453-460. PubMed ID: 30679762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer.
    Talala K; Heinävaara S; Taari K; Tammela TLJ; Kujala P; Stenman UH; Malila N; Auvinen A
    Cancer Med; 2020 Aug; 9(15):5643-5654. PubMed ID: 32500650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.